A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

NCT01689519 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

495

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Placebo
DRUG: Vemurafenib
DRUG: Cobimetinib

Sponsor

Hoffmann-La Roche